Safe and Effective Use of Combination Antiretroviral Treatment

References

• Torres RA, Barr M. Impact of combination therapy for HIV infection on in patient census. N Engl J Med 1997; 21: 1531–2.
   Google Scholar
• Gulick R, Squires K, Powderly W, et al. An open-label, randomized, comparative study of d4T+3TC+IDV versus ZDV+3TC+IDV in treatment naive HIV-infected patients (START I). In conference record 12th World AIDS Conference Geneva, Abstract 12223.
   Google Scholar
• BHIVA Guidelines Co-ordinating Committee: British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314–6.
   Google Scholar
• Carpenter ChCJ, Fischl MA, Hammer SM, et al. Antiretroviral Therapy for HIV Infection in 1997. JAMA 1998; 280 (1): 78–86.
   Google Scholar
• Centers for Disease Control and Prevention, Report of the NIH Panel to define principles of therapy of HIV infection and Guidelines for the use of Antiretroviral Agents in HIV-infected adults and adolescents. MMWR 1998; 47: 1–82.
   Google Scholar
• Hammer SM, Yeni P. Antiretroviral therapy: where are we? AIDS 1998; 12: S181-S188.
   Google Scholar
• Carpenter ChCJ, Fischl MA, Hammer SM, et al. Antiretroviral Therapy for HIV Infection in 1998. JAMA 1998; 280 (1): 78–86.
   Google Scholar
• Carpenter C, Feinberg M, et al. Report of the NIH Panel to define principles of therapy of HIV infection. Ann Int Med 1998; 128: 1057–1078.
   Google Scholar
• Fauci AS, Bartlett JG, et al. Guidelines for the use of anti-retroviral agents in HIV-infected adults and adolescents. Ann Int Med 1998; 128: 1079–1100.
   Google Scholar
• Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
   Google Scholar
• Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. The Lancet 1998; 351: 1328.
   Google Scholar
• Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retroviral 1995; 10: S28-S33.
   Google Scholar
• Chun TW, Struyver L, Mizell SB, et al. Presence of an inducable HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94: 13193–7.
   Google Scholar
• Pantaleo G, Perrin L. Can HIV be eradicated. AIDS 1998; 12 (suppl A): S175-S180.
   Google Scholar
• Raboud JM, Montaner JSG, Conway B, et al. Variation in plasma RNA levels, CD4 cell count and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis 1996; 174: 191–4.
   Google Scholar
• Styrt BA, Piazza-Hepp TD, Chikami GK. Clinical toxicity of antiretroviral nucleoside analogs. Antiviral Res 1996; 31: 121–135.
   Google Scholar
• Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281–92.
   Google Scholar
• Colebunders R, De Droogh E, Pelgrom Y, Depraetere K, De Jonghe P. Painful hyperaesthesia caused by protease inhibitors? Infection 1998; 26: 250–1.
   Google Scholar
• Brichacek B, Swindells S, Janoff EN, Pirrucello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal medicine. J Infect Dis 1996; 174: 1191–9.
   Google Scholar
• Havlir DV, Lange JMA. New antiretrovirals and new combinations. AIDS 1998; 12 (suppl A): S165-S174.
   Google Scholar
• De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with whicht they interact. Adv Virus Res 1993; 42: 1–55.
   Google Scholar
• Hertoghs K., M. Conant, P. Schel, A. et al. The RT-Antivirogram: a rapid method to determine phenotypic (multi) drug resistance in plasma of patients treated with various HIV-1 RT inhibitors. Antivir Ther 1 (Suppl. 1): 40.
   Google Scholar
• De Wolf F, De Jong JJ, Hertogs K, Danner SA, Lange JMA, Goudsmit J. Virologische evaluatie van behandeling van HIV-geïnfecteerden met (combinaties van) antiretrovirale middelen in het Academisch Medisch Centrum Amsterdam, 1996/97. Ned Tijdschr Geneeskd 1998; 142 (11): 573–8.
   Google Scholar
• Taburet AM, Singlas E. Drug Interactions with Antiviral Drugs. Clin Pharmacol 1996; 30 (5): 385–401.
   Google Scholar
• Centers for Disease Control and Prevention. Clinical Update. Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996; 45: 921–925.
   Google Scholar
• Morris LS, Schulz RM. Patient compliance - an overview. J Clin Pharm Ther 1992; 17: 283–95.
   Google Scholar
• Anderson RJ, Kirk LM. Methods of improving patients compliance in chronic disease states. Arch Intern Med 1982; 142: 1673–5.
   Google Scholar
• Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665–70.
   Google Scholar
• Singh N, Squier C, Sivek C, Wagener M, Hong Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care 1996; 3: 261–9.
   Google Scholar
• Rawlings JE, Holmes J, Belton B, Selwyn P, Friedland G. Changes in HIV/AIDS patterns of care and estimated costs at an urban medical center during the era of Haart. In conference record 12th World AIDS Conference Geneva, Abstract 42430.
   Google Scholar